The therapeutic potential of mTOR inhibitors in breast cancer.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  British Journal of Clinical Pharmacology

• Publication date

  2016-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/bcp.12958PMID 27059645PMCID PMC5061784
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Blocking mammalian target of rapamycin alleviates bone cancer pain and morphine tolerance via µ‐opioid receptor

  2016cited by this paper
• The therapeutic potential of mTOR inhibitors in breast cancer.

  2016cited by this paper
• Novel roles of androgen receptor, epidermal growth factor receptor, TP53, regulatory RNAs, NF-kappa-B, chromosomal translocations, neutrophil associated gelatinase, and matrix metalloproteinase-9 in prostate cancer and prostate cancer stem cells.

  2016cited by this paper
• Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.

  2016cited by this paper
• NGF and ProNGF: Regulation of neuronal and neoplastic responses through receptor signaling.

  2015cited by this paper
• Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer.

  2015cited by this paper
• Roles of EGFR and KRAS and their downstream signaling pathways in pancreatic cancer and pancreatic cancer stem cells.

  2015cited by this paper
• Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.

  2015cited by this paper
• Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.

  2015cited by this paper
• Current medical treatment of estrogen receptor-positive breast cancer.

  2015cited by this paper
• Validation of p27KIP1 expression levels as a candidate predictive biomarker of response to rapalogs in patient-derived breast tumor xenografts

  2015cited by this paper
• Oral ridaforolimus plus trastuzumab for patients with HER2+ trastuzumab-refractory metastatic breast cancer.

  2015cited by this paper
• Precision medicine for metastatic breast cancer.

  2015cited by this paper
• Inhibition of Autophagy Increases Proliferation Inhibition and Apoptosis Induced by the PI3K/mTOR Inhibitor NVP-BEZ235 in Breast Cancer Cells.

  2015cited by this paper
• PLC and PI3K/Akt/mTOR signalling in disease and cancer.

  2015cited by this paper
• Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours.

  2015cited by this paper
• Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy

  2015cited by this paper
• A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies

  2015cited by this paper
• S6 kinase signaling: tamoxifen response and prognostic indication in two breast cancer cohorts.

  2015cited by this paper
• Everolimus in the Treatment of Metastatic Breast Cancer

  2015cited by this paper
• Patient-derived xenograft models of breast cancer and their predictive power

  2015cited by this paper
• PTEN inhibitors: an evaluation of current compounds.

  2015cited by this paper
• Epithelial to mesenchymal transition is associated with rapamycin resistance

  2015cited by this paper
• Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines

  2015cited by this paper
• Reference Intervals for Hemoglobin and Age- and Gender-Related Trends in the Population of Southwest China.

  2015cited by this paper
• Combined Use of Metformin and Everolimus Is Synergistic in the Treatment of Breast Cancer Cells

  2015cited by this paper
• Addition of rapamycin and hydroxychloroquine to metronomic chemotherapy as a second line treatment results in high salvage rates for refractory metastatic solid tumors: a pilot safety and effectiveness analysis in a small patient cohort

  2015cited by this paper
• AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules

  2015cited by this paper
• Everolimus Plus Exemestane for the Treatment of Advanced Breast Cancer: A Review of Subanalyses from BOLERO-2

  2015cited by this paper
• A phase I dose‐escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC‐223 in patients with advanced solid tumors or multiple myeloma

  2015cited by this paper
• The Combination of Rapamycin and Resveratrol Blocks Autophagy and Induces Apoptosis in Breast Cancer Cells

  2015cited by this paper
• Rapamycin-induced G1 cell cycle arrest employs both TGF-β and Rb pathways.

  2015cited by this paper
• mTORC1 directly phosphorylates and activates ERα upon estrogen stimulation

  2015cited by this paper
• Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor

  2015cited by this paper
• Lipin-1 regulates cancer cell phenotype and is a potential target to potentiate rapamycin treatment

  2015cited by this paper
• mTOR inhibitors counteract tamoxifen-induced activation of breast cancer stem cells.

  2015cited by this paper
• Targeted therapies for ER+/HER2- metastatic breast cancer

  2015cited by this paper
• Implication of PI3K/Akt pathway in pancreatic cancer: When PI3K isoforms matter?

  2015cited by this paper
• AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1/4E-BP1 axis

  2015cited by this paper
• Roles of signaling pathways in drug resistance, cancer initiating cells and cancer progression and metastasis.

  2015cited by this paper
• Stomatitis Associated With Use of mTOR Inhibitors: Implications for Patients With Invasive Breast Cancer.

  2015cited by this paper
• Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention

  2014cited by this paper
• GSK-3 as potential target for therapeutic intervention in cancer

  2014cited by this paper
• Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†.

  2014cited by this paper
• Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2

  2014cited by this paper
• Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†.

  2014cited by this paper
• Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†.

  2014cited by this paper
• Mammalian target of rapamycin (mTOR) inhibitors and combined chemotherapy in breast cancer: a meta-analysis of randomized controlled trials.

  2014cited by this paper
• Tumor promoter-induced cellular senescence: cell cycle arrest followed by geroconversion

  2014cited by this paper
• Class I PI 3-kinases signaling in platelet activation and thrombosis: PDK1/Akt/GSK3 axis and impact of PTEN and SHIP1.

  2014cited by this paper
• Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer

  2014cited by this paper
• Targeting breast cancer initiating cells: advances in breast cancer research and therapy.

  2014cited by this paper
• PTEN expression and function in adult cancer stem cells and prospects for therapeutic targeting.

  2014cited by this paper
• Targeting signaling pathways in T-cell acute lymphoblastic leukemia initiating cells.

  2014cited by this paper
• Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.

  2014cited by this paper
• Novel approaches to target NF-κB and other signaling pathways in cancer stem cells.

  2014cited by this paper
• NOTCH and PTEN in prostate cancer.

  2014cited by this paper
• An expanding role for RAS GTPase activating proteins (RAS GAPs) in cancer.

  2014cited by this paper
• Diverse roles of GSK-3: tumor promoter-tumor suppressor, target in cancer therapy.

  2014cited by this paper
• Signaling specificity in the Akt pathway in biology and disease.

  2014cited by this paper
• PTEN and leukemia stem cells.

  2014cited by this paper
• Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2.

  2014cited by this paper
• Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2.

  2013cited by this paper
• Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis

  2013cited by this paper
• Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer.

  2013cited by this paper
• Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer.

  2013cited by this paper
• Health-related quality of life and disease symptoms in postmenopausal women with HR+, HER2− advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy

  2013cited by this paper
• Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2

  2013cited by this paper
• Appropriate design of prospective studies.

  2013cited by this paper
• A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure

  2013cited by this paper
• Patient-derived breast tumor xenografts facilitating personalized cancer therapy

  2013cited by this paper
• Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.

  2012cited by this paper
• Phase II trial of temsirolimus in patients with metastatic breast cancer

  2012cited by this paper
• Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study.

  2012cited by this paper
• Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.

  2012cited by this paper
• Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

  2012cited by this paper
• Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures

  2012cited by this paper
• Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy.

  2011cited by this paper
• PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer

  2011cited by this paper
• Improved classification of breast cancer by analysis of genetic alterations and gene expression profiling

  2011cited by this paper
• Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer

  2010cited by this paper
• Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer

  2010cited by this paper
• Evaluating temsirolimus activity in multiple tumors: a review of clinical trials.

  2009cited by this paper
• Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.

  2009cited by this paper
• Inhibition of Mammalian Target of Rapamycin Is Required for Optimal Antitumor Effect of HER2 Inhibitors against HER2-Overexpressing Cancer Cells

  2009cited by this paper
• Improved clinical and cell cycle response with an mTOR inhibitor, daily oral RAD001 (everolimus) plus letrozole versus placebo plus letrozole in a randomized phase II neoadjuvant trial in ER+ breast cancer

  2008cited by this paper
• Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data.

  2008cited by this paper
• Multicenter phase I clinical trial of daily and weekly RAD001 in combination with vinorelbine and trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab

  2008cited by this paper
• A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

  2007cited by this paper
• Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer.

  2005cited by this paper
• PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

  2004cited by this paper
• International Journal of Women's Health Dovepress Clinical Utility of Exemestane in the Treatment of Breast Cancer

  year unknowncited by this paper
• Cancer Management and Research Dovepress Clinical Implications of Recent Studies Using Mtor Inhibitors to Treat Advanced Hormone Receptor-positive Breast Cancer

  year unknowncited by this paper

• Kanser Tedavisinde PI3K/AKT/mTOR Yolunun Hedeflenmesi: Yeni Nesil mTOR İnhibitörlerine Güncel Bir Değerlendirme

  2025cites this paper
• Decoding estrogen receptor and GPER biology: structural insights and therapeutic advances in ERα−positive breast cancer

  2025cites this paper
• Targeting mTOR Kinase for Cancer Treatment: A Comprehensive Review With Clinical Insights

  2025cites this paper
• Real-world evidence couples genomic biomarkers with therapeutic outcomes for canine hemangiosarcoma

  2025cites this paper
• mTOR inhibitors in targeting autophagy and autophagy-associated signaling for cancer cell death and therapy.

  2025cites this paper
• ADAMs contribute to triple negative breast cancer via mTORC1 pathway: targeting ADAM-mTOR axis improves efficacy.

  2025cites this paper
• Ilex latifolia Improves the Anti-Tumor Effectiveness of Rapamycin Against Breast Cancer In Vitro and In Vivo

  2025cites this paper
• Ginsenoside Rh2 regulates cardiomyocyte autophagy-dependent apoptosis through the PI3K-Akt-mTOR signaling pathway to attenuate doxorubicin-induced cardiotoxicity

  2025cites this paper
• Integrating RNA-seq and scRNA-seq to explore the prognostic features and immune landscape of exosome-related genes in breast cancer metastasis

  2025cites this paper
• mTOR Levels and Metastasis in Luminal Breast Cancer: Implications for Prognosis and Treatment

  2025cites this paper
• Metabolic reprogramming in breast cancer: Pathways driving progression, drug resistance, and emerging therapeutics.

  2025cites this paper
• Predictive, preventive, and personalized medicine in breast cancer: targeting the PI3K pathway

  2024cites this paper
• Anticancer potential of delphinidin and its derivatives: therapeutic and mechanistic insights

  2024cites this paper
• SnoRNA U50A mediates everolimus resistance in breast cancer through mTOR downregulation

  2024cites this paper
• A modular microfluidic platform to study how fluid shear stress alters estrogen receptor phenotype in ER+ breast cancer cells

  2024cites this paper
• Combined Effect of Sertraline and Capecitabine on Breast Cancer Cell Lines In Vitro and In Silico Evidence for Synergistic Interaction

  2024cites this paper
• Targeting the RAS upstream and downstream signaling pathway for Cancer treatment.

  2024cites this paper
• AEGAN-Pathifier: a data augmentation method to improve cancer classification for imbalanced gene expression data

  2024cites this paper
• Precision oncology in patients with breast cancer: towards a ‘screen and characterize’ approach

  2024cites this paper
• Role of mammalian target of rapamycin (mTOR) signalling in oncogenesis.

  2023cites this paper
• Conventional and Advanced Therapeutic Approaches in Breast Cancer Treatment

  2023cites this paper
• A modular microfluidic platform to study how fluid shear stress alters estrogen receptor phenotype in ER+ breast cancer cells

  2023cites this paper
• Breast Cancer Associated Conventional and Advanced Therapies 

  2023cites this paper
• Exemestane-Everolimus-Induced Angioedema in a Woman With Metastatic Breast Cancer: A Case Report and Review

  2023cites this paper
• Exploring the role of PI3K/AKT/mTOR inhibitors in hormone-related cancers: A focus on breast and prostate cancer.

  2023cites this paper
• A prognostic model related to necrotizing apoptosis of breast cancer based on biorthogonal constrained depth semi-supervised nonnegative matrix decomposition and single-cell sequencing analysis.

  2023cites this paper
• A systems biology approach and in vitro experiment indicated Rapamycin targets key cancer and cell cycle‐related genes and miRNAs in triple‐negative breast cancer cells

  2023cites this paper
• Administration of inhibitory molecules through nanoparticles in breast cancer therapy.

  2023cites this paper
• Acalabrutinib as a novel hope for the treatment of breast and lung cancer: an in-silico proof of concept

  2023cites this paper
• Role of the Dietary Phytochemical Curcumin in Targeting Cancer Cell Signalling Pathways

  2023cites this paper
• Aquaporins in Tumor.

  2023cites this paper
• New and Emerging Targeted Therapies for Advanced Breast Cancer

  2022cites this paper
• Pooled genome-wide CRISPR activation screening for rapamycin resistance genes in Drosophila cells

  2022cites this paper
• Multiplexed and reproducible high content screening of live and fixed cells using Dye Drop

  2022cites this paper
• Focal Adhesion Kinase Provides a Collateral Vulnerability That Can Be Leveraged to Improve mTORC1 Inhibitor Efficacy

  2022cites this paper
• Identifying drivers of breast cancer metastasis in progressively invasive subpopulations of zebrafish-xenografted MDA-MB-231

  2022cites this paper
• Electronic, spectroscopic, molecular docking and molecular dynamics studies of neutral and zwitterionic forms of 3, 4-dihydroxy-L-phenylalanine: A novel lung cancer drug

  2022cites this paper
• Novel Zinc and Vanadium (V) Hydroquinonate Complexes: Synthesis and Biological Evaluation

  2022cites this paper
• Chamaejasmenin B, an Inhibitor for Metastatic Outgrowth, Reversed M2-Dominant Macrophage Polarization in Breast Tumor Microenvironment

  2021cites this paper
• Sensitivity of pancreatic cancer cells to chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals can be regulated by WT-TP53.

  2021cites this paper
• Identification of Common Pathogenetic Processes between Schizophrenia and Diabetes Mellitus by Systems Biology Analysis

  2021cites this paper
• Phase 2 study of anastrozole in patients with estrogen receptor/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas: The PARAGON trial (ANZGOG 0903).

  2021cites this paper
• The potential of rapalogs to enhance resilience against SARS-CoV-2 infection and reduce the severity of COVID-19

  2021cites this paper
• Recent Advances in the Development of PI3K/mTOR-Based Anticancer Agents: A Mini Review.

  2021cites this paper
• Autophagy Triggers Tamoxifen Resistance in Human Breast Cancer Cells by Preventing Drug-Induced Lysosomal Damage

  2021cites this paper
• Everolimus Related Fulminant Hepatitis in Pancreatic Neuroendocrine Tumor With Liver Metastases: A Case Report and Literature Review

  2021cites this paper
• Triple Negative Breast Cancer

  2021cites this paper
• LY-294002 enhances the chemosensitivity of liver cancer to oxaliplatin by blocking the PI3K/AKT/HIF-1α pathway

  2021cites this paper
• A patent review of mTOR inhibitors for cancer therapy (2011–2020)

  2021cites this paper
• Taxifolin, a novel food, attenuates acute alcohol-induced liver injury in mice through regulating the NF-κB-mediated inflammation and PI3K/Akt signalling pathways

  2021cites this paper
• Discovering common pathogenetic processes between COVID-19 and diabetes mellitus by differential gene expression pattern analysis

  2021cites this paper
• The genomic architecture of metastasis in breast cancer: focus on mechanistic aspects, signalling pathways and therapeutic strategies

  2021cites this paper
• Multiplexed and reproducible high content screening of live and fixed cells using the Dye Drop method

  2021cites this paper
• The Role of Curcumin in Cancer Treatment

  2021cites this paper
• Molecular Prognostic Factors for Distant Metastases in Premenopausal Patients with HR+/HER2− Early Breast Cancer

  2021cites this paper
• miRNA-425-5p enhances diffuse large B cell lymphoma growth by targeting PTEN

  2021cites this paper
• Zebrafish xenografts to isolate unique human breast cancer metastatic cell populations

  2021cites this paper
• Targeting Epithelial-to-Mesenchymal Transition for Breast Cancer Stem Cells Therapeutics

  2021cites this paper
• The Impact of Everolimus and Radiation Therapy on Pulmonary Fibrosis

  2020cites this paper
• Aquaporin-7 Regulates the Response to Cellular Stress in Breast Cancer

  2020cites this paper
• Computer-Aided Ligand Discovery for Estrogen Receptor Alpha

  2020cites this paper
• Landscape of clinically actionable mutations in breast cancer ‘A cohort study’

  2020cites this paper
• Treatment of keloids through Runx2 siRNA-induced inhibition of the PI3K/AKT signaling pathway

  2020cites this paper
• Mass spectrometry proteomics reveals a function for mammalian CALCOCO1 in MTOR-regulated selective autophagy

  2020cites this paper
• Understanding Breast cancer: from conventional therapies to repurposed drugs.

  2020cites this paper
• Therapeutic resistance in breast cancer cells can result from deregulated EGFR signaling.

  2020cites this paper
• Amplification of 8p11.23 in cancers and the role of amplicon genes.

  2020cites this paper
• 8p11.23 Amplification in Breast Cancer: Molecular Characteristics, Prognosis and Targeted Therapy

  2020cites this paper
• Molecular Basis Associated with the Control of Primordial Follicle Activation During Transplantation of Cryopreserved Ovarian Tissue

  2020cites this paper
• Recent advances of therapeutic targets based on the molecular signature in breast cancer: genetic mutations and implications for current treatment paradigms

  2019cites this paper
• Targeting mTOR in Acute Lymphoblastic Leukemia

  2019influential citation
• The role of miRNAs in the invasion and metastasis of cervical cancer

  2019cites this paper
• miR-16-2-3p inhibits cell proliferation and migration and induces apoptosis by targeting PDPK1 in maxillary primordium mesenchymal cells

  2019cites this paper
• Kaempferol promotes bone formation in part via the mTOR signaling pathway

  2019cites this paper
• Antitumor effects and mechanisms of 1,25(OH)2D3 in the Pfeiffer diffuse large B lymphoma cell line

  2019cites this paper
• Mechanisms of resistance to estrogen receptor modulators in ER+/HER2− advanced breast cancer

  2019cites this paper
• 2-Oxonanonoidal Antibiotic Actinolactomycin Inhibits Cancer Progression by Suppressing HIF-1α

  2019cites this paper
• Feedback Activation of SGK3 and AKT Contributes to Rapamycin Resistance by Reactivating mTORC1/4EBP1 Axis via TSC2 in Breast Cancer

  2019cites this paper
• Impact of Genomics on Personalization of Breast Cancer Care

  2018cites this paper
• Mechanisms of resistance in estrogen receptor positive breast cancer: overcoming resistance to tamoxifen/aromatase inhibitors

  2018cites this paper
• Chronotherapy with defective circadian clock?

  2018cites this paper
• Delphinidin induced protective autophagy via mTOR pathway suppression and AMPK pathway activation in HER-2 positive breast cancer cells

  2018cites this paper
• Drug discovery targeting the mTOR pathway.

  2018cites this paper
• Functional and genomic characterisation of a xenograft model system for the study of metastasis in triple-negative breast cancer

  2018cites this paper
• Everolimus-induced pulmonary toxicity

  2018cites this paper
• A meta-analysis and bioinformatics exploration of the diagnostic value and molecular mechanism of miR-193a-5p in lung cancer

  2018cites this paper
• Curcumin inhibits proliferation and promotes apoptosis of breast cancer cells

  2018cites this paper
• Introduction of WT-TP53 into pancreatic cancer cells alters sensitivity to chemotherapeutic drugs, targeted therapeutics and nutraceuticals.

  2018cites this paper
• Dosing time dependent in vitro pharmacodynamics of Everolimus despite a defective circadian clock

  2018cites this paper
• Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update

  2018cites this paper
• Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer

  2018cites this paper
• Fenofibrate inhibits mTOR-p70S6K signaling and simultaneously induces cell death in human prostate cancer cells.

  2018cites this paper
• Metformin in Lung Cancer: Review of in Vitro and in Vivo Animal Studies

  2017cites this paper
• Milk’s Role as an Epigenetic Regulator in Health and Disease

  2017cites this paper
• G0S2 represses PI3K/mTOR signaling and increases sensitivity to PI3K/mTOR pathway inhibitors in breast cancer

  2017cites this paper
• Dual abrogation of MNK and mTOR: a novel therapeutic approach for the treatment of aggressive cancers.

  2017cites this paper
• Traditional Chinese medicine Danggui Buxue Tang inhibits colorectal cancer growth through induction of autophagic cell death

  2017cites this paper
• Treatment of melanoma with selected inhibitors of signaling kinases effectively reduces proliferation and induces expression of cell cycle inhibitors

  2017cites this paper
• MicroRNA-100 shuttled by mesenchymal stem cell-derived exosomes suppresses in vitro angiogenesis through modulating the mTOR/HIF-1α/VEGF signaling axis in breast cancer cells

  2017cites this paper
• A Comprehensive Review of mTOR-Inhibiting Pharmacotherapy for the Treatment of Non-Infectious Uveitis.

  2017cites this paper